Quarterly ResultMay 11, 2026, 07:32 AM
Dyne Therapeutics Q1 Net Loss Widens to $120.9M
AI Summary
Dyne Therapeutics reported a net loss of $120.9 million for Q1 2026, widening from $115.4 million in Q1 2025. The company's cash and cash equivalents decreased to $753.1 million from $893.4 million at the end of 2025, with net cash used in operating activities increasing to $144.9 million. Dyne expects its current capital to fund operations for at least 12 months but acknowledges the need for substantial additional funding to advance its product candidates, which are not expected to be commercialized before 2027.
Key Highlights
- Net loss for Q1 2026 was $(120.9) million, compared to $(115.4) million in Q1 2025.
- Net loss per share for Q1 2026 was $(0.73), compared to $(1.05) in Q1 2025.
- Cash and cash equivalents were $753.1 million as of March 31, 2026, down from $893.4 million at Dec 31, 2025.
- Marketable securities totaled $219.1 million as of March 31, 2026.
- Net cash used in operating activities increased to $(144.9) million in Q1 2026 from $(105.9) million in Q1 2025.
- Research and development expenses decreased to $100.9 million in Q1 2026 from $106.4 million in Q1 2025.
- General and administrative expenses increased to $24.4 million in Q1 2026 from $15.9 million in Q1 2025.
- Long-term debt, net, was $149.4 million as of March 31, 2026.